Standards of care for type 2 diabetes in China.

Epidemiology of T2DM in China

Epidemiology of T2DM

The past 30 years have witnessed significant increases in the prevalence of type 2 diabetes mellitus (T2DM) in China. A 1980 epidemiological survey that included 30 000 people from 14 provinces and cities nationwide indicated that the prevalence of diabetes was 0.67% 1. A 1994–1995 epidemiological survey that included 210 000 people from 19 provinces and cities found that the prevalence of diabetes was 2.5% among individuals who were 25–64 years old (with a population standardized rate of 2.2%) and that the prevalence of impaired glucose tolerance was 3.2% (with a population standardized rate of 2.1%) 2. A national nutrition survey conducted in 2002, showed that the prevalences of diabetes were 4.5% and 1.8% among people over 18 years in the urban and rural areas, respectively 3. In 2007–2008, the Chinese Diabetes Society (CDS) performed an epidemiological survey in 14 provinces and cities nationwide. After adopting a weighted analysis that took into account factors such as gender, age, rural and urban distributions and regional differences, the estimated prevalence of diabetes was 9.7% in adults over 20 years of age in China 4, accounting for 92.4 million adults with diabetes (43.1 million rural residents and 49.3 urban residents) (Table 1).

Table 1

Summary of five nationwide epidemiological surveys of diabetes in China

Year of survey (diagnostic criteria)	Number of surveyed people (10 000)	Age (years)	Prevalence of diabetes (%)	Prevalence of impaired glucose tolerance (%)	Screening method
1980a 1 (Lanzhou standard)	30	Entire population	0.67	—	Urine glucose + 2h PG (steamed bread tolerance test) for screening the high risk subjects
1986 49 (WHO 1985)	10	25–64	1.04	0.68	2h PG (steamed bread tolerance test) for screening the high risk subjects
1994 2 (WHO 1985)	21	25–64	2.5	3.2	2h PG (steamed bread tolerance test) for screening the high risk subjects
2002 3 (WHO 1999)	10	≥18	4.5 (urban)	IFG 2.7	FPG screening of the high‐risk group
			1.8 (rural)	IFG 1.6
2007–2008 4 (WHO 1999)	4.6	≥20	9.7	15.5b	One‐step OGTT method

1 mmol/L = 18 mg/dL.

FPG: fasting plasma glucose; WHO: World Health Organization; IFG: impaired fasting glucose; OGTT: oral glucose tolerance test; 2 hPG, 2‐h postprandial blood glucose; —, no data.

Diagnostic criteria are FPG ≥130 mg/dL and/or 2 hPG ≥200 mg/dL and/or more than three items on the OGTT curve that are above the diagnostic criteria [0′ 125, 30′ 190, 60′ 180, 120′ 140, and 180′ 125 mg/dL, in which 0′, 30′, 60′, 120′ and 180′ are time points (min), and 30′ or 60′ is one time point; the glucose measurement uses the o‐toluidine method with 100 g of glucose].

Prediabetes, including IFG, IGT or both (IFG/IGT).

In summary, the current epidemic of diabetes in China shows the following characteristics:

T2DM accounts for more than 90% of the overall population with diabetes in China; type 1 diabetes mellitus (T1DM) accounts for approximately 5.0%, and other types of diabetes account for only 0.7% 5. Notably, due to lack of reliable data on T1DM incidences and prevalences over the past years in China, further investigation has to be conducted to report the proportion.

The prevalences of diabetes appear to be correlated with degree of economic development: in the 1994 survey, the prevalence of diabetes among the high‐income group was 2–3 times higher than that of the low‐income group 2. A latest study showed that the prevalence of diabetes in developed regions was still significantly higher than that in under‐developed regions, and the prevalence rate in cities was higher than those in rural areas 4.

A large proportion of diabetes is undiagnosed: in the 2007–2008 national survey among adult population over 20 years, patient with newly diagnosed diabetes accounted for 60% of total diabetes population.

Male gender and low‐education levels are risk factors of diabetes: in the 2007–2008 survey, after adjusting for other risk factors, the risk for men were found increased by 26% compared with that for women, and risk of diabetes among people without college education was 57% higher than those with college or higher education 4.

Phenotypic characteristics: the average body mass index (BMI) of China's T2DM population is approximately 25 kg/m2, whereas the average BMI of Caucasian diabetes population is generally higher than 30 kg/m2. In China, there is a larger proportion characterized by postprandial hyperglycaemia. Further, postprandial hyperglycaemia alone accounts for nearly 50% of the overall newly diagnosed population 6.

Cardiovascular diseases are common among diabetic patients. Because diabetes population in China shows a shorter disease duration late chronic complications such as diabetic retinopathy and diabetic nephropathy may pose great challenges in the future.

Diagnosis and classification of diabetes mellitus

Diagnosis of diabetes

This guideline recommends the World Health Organization's (WHO) (1999) the criteria for diagnosis and classification of diabetes, and classification of metabolic status (Table 2): either the fasting plasma glucose (FPG) or the 2‐h plasma glucose (2‐h PG) value after a 75‐g oral glucose tolerance test (OGTT) can be used alone for epidemiological investigations or mass screenings 7. However, the data in China include only the FPG levels, resulting in a larger proportion of diabetes being missed. The ideal investigation should simultaneously check FPG and 2‐h PG after the glucose load; blood glucose levels at other time points after the OGTT are not used as diagnostic criteria.

Table 2

Diagnostic criteria for diabetes and prediabetes

Diagnostic methods	Venous plasma glucose level (mmol/L)
(1) Typical symptoms of diabetes (polydipsia, polyuria, polyphagia and weight loss) plus random blood glucose testing	≥11.1
or
(2) Fasting plasma glucose	≥7.0
or
(3) 2 h after the glucose load test	≥11.1
Individuals who do not present diabetes symptoms should be re‐tested on a separate day.

The fasting state refers to not eating for at least 8 h. Random blood glucose refers to the blood glucose level at any time of day regardless of the time of the last meal, which cannot be used to diagnose impaired fasting glucose or impaired glucose tolerance.

Individuals with impaired fasting glucose should undergo the OGTT to reduce the number of missed diabetes diagnoses.

The issue of using HbA1c for diabetes diagnosis

The 2010 American Diabetes Association guidelines added glycated haemoglobin (HbA1c) ≥6.5% as a diagnostic criterion for diabetes 8. In 2011, the WHO also recommended that wherever conditions permit, countries and regions may consider adopting this cut‐off point for diabetes diagnosis 9. However, given that the HbA1c test is not yet commonly applied in China, the insufficient degree of standardization, and the fact that the instruments and quality control for measuring HbA1c are currently unable to meet the current diagnostic standard for diabetes, this guideline does not recommend the use of HbA1c for diagnosis of diabetes in China. Nevertheless, for hospitals that use a standardized HbA1c assay with a normal reference value of 4.0–6.0% and strict quality control, HbA1c ≥6.5% can be used as a reference when diagnosing diabetes.

Classification of diabetes mellitus

This guideline adopts the diabetes aetiology classification system proposed by the WHO (1999), which divides diabetes into four major categories based on aetiological evidence, that is, T1DM, T2DM, gestational diabetes mellitus (GDM) and special types of diabetes.

Primary, secondary and tertiary diabetes prevention

Primary, secondary and tertiary prevention of T2DM

The goal of primary prevention is to prevent the occurrence of T2DM. Secondary prevention aims to prevent diabetic complications in patients with T2DM. Tertiary prevention aims to delay the progression of diabetic complications, to reduce morbidity and mortality and to improve the patients' quality of life.

Strategies for the primary prevention of T2DM

Risk factors and intervention strategies for T2DM

The risk of T2DM depends primarily on the patient's number and degree of risk factors. Some of these factors cannot be changed, whereas others can (Table 3).

Table 3

Risk factors for type 2 diabetes mellitus

Unchangeable risk factors	Changeable risk factors
Age	Prediabetes (impaired glucose tolerance or combined impaired fasting glucose), the most important risk factor
Family history or genetic predisposition	Metabolic syndrome
Ethnicity	Overweight, obesity and depression
History of gestational diabetes mellitus or women with history of delivery of a baby weighing ≥ 4 kg	Excess dietary caloric intake, sedentary or physically inactive
Polycystic ovary syndrome	Use of drugs that can increase the risk of diabetes
Intrauterine growth retardation or premature birth	Social environments that can cause obesity or diabetes

Diabetes screening of high‐risk populations

Primary prevention efforts for T2DM should adopt hierarchical management approaches based on the differences between the high‐risk population and general population. It is not feasible either to screen prediabetes in the entire Chinese population or to systematically identify high risk groups by blood glucose tests, considering the huge population in China. Therefore, the identification of high‐risk groups relies primarily on opportunistic screening (e.g. screening that occurs during routine physical examinations or during treatment for other diseases).

Screening of diabetes benefits the early diagnosis of diabetes and improves the prevention and treatment of diabetes and its complications. Therefore, when conditions permit, high‐risk groups should be targeted for diabetes screening.

Definition of the high‐risk diabetes group among adults are as follows: adults (>18 years) with one or more of the following diabetes risk factors: (1) age ≥40 years, (2) history of impaired glucose regulation, (3) overweight (BMI ≥24 kg/m2) or obesity (BMI ≥28 kg/m2) and/or central obesity (male waist circumference ≥90 cm and female waist circumference ≥85 cm), (4) sedentary lifestyle, (5) first‐degree relatives with T2DM, (6) women who delivered a baby weighing ≥4 kg) or were diagnosed with GDM (7) hypertension [systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg (1 mmHg = 0.133 kPa)] or on therapy for hypertension, (8) dyslipidemia [high‐density lipoprotein cholesterol (HDL‐C) ≤0.91 mmol/L (≤35 mg/dL) and triglycerides ≥2.22 mmol/L (≥200 mg/dL)] or on therapy for hyperlipidemia, (9) atherosclerotic cardiovascular disease, (10) a transient history of steroid diabetes, (11) polycystic ovary syndrome and (12) long‐term use of antipsychotics and/or antidepressant treatment. Of the aforementioned factors, impaired glucose regulation is the most important high‐risk factor: approximately 5%–10.0% of patients with impaired glucose tolerance progress to T2DM annually 10.

Diabetes screening age and frequency

For adults in the high‐risk group, diabetes screening should be performed as early as possible, regardless of age; for populations with no diabetes risk factors other than age, screening should begin at ≥40 years of age. For children and adolescents at a high risk for diabetes, screening should begin at age 10 years; however, for individuals with an earlier onset of puberty, this guideline recommends that screening starts at puberty. Those whose initial screening results are normal are recommended to undergo screening again at least once every 3 years.

Diabetes screening strategy

At medical institutions with a qualified laboratory, diabetes screening is recommended for high‐risk patients during their visits or physical examinations.

Diabetes screening method

The fasting blood glucose test is a simple diabetes screening method that should be used for routine screening, albeit there's risk of missing diagnosis. When conditions permit, the OGTT (both FPG and 2‐h PG after glucose load) should be performed as often as possible. HbA1c testing is not currently recommended as a routine screening method.

Diabetes screening of the general population

To improve the effectiveness of diabetes screening for the general population, targeted diabetes screening should occur according to the individual's degree of diabetes risk.

T2DM prevention through intensive lifestyle intervention

Multiple randomized and controlled studies have shown that people with impaired glucose tolerance can be delayed or prevented from developing to T2DM, through appropriate lifestyle interventions, 11, 12, 13. In a study conducted in Daqing, China, patients in the lifestyle intervention group were asked to increase vegetable intake and reduce intake of alcohol and monosaccharides, and those who were defined as overweight or obese (BMI >25 kg/m2) were encouraged to lose weight, increase intensity of physical activity by performing at least 30 min of moderately intense activity per day. After a 6‐year lifestyle intervention, the cumulative incidence of T2DM risk for the subsequent 14 years decreased by 43% 14. The lifestyle intervention groups in the Finnish Diabetes Prevention Study 15 and the American Diabetes Prevention Program 16 also demonstrated that the intervention could significantly reduce the risk of developing T2DM among patients with impaired glucose tolerance.

This guideline recommends that patients with prediabetes lower the risk of diabetes through diet control and exercise; that patients should receive regular follow‐up that provides psychosocial support to ensure patients' long‐term adherence to a healthy lifestyle; that blood glucose levels should be regularly tested; that the cardiovascular disease risk factors (such as smoking, hypertension and dyslipidemia) should be closely monitored; and that appropriate intervention measures should be provided. The specific objectives are (1) the BMI of overweight or obese patients should be lowered to approximately 24 kg/m2 or weight loss of at least 5–10% should be achieved, (2) the patients' total daily caloric intake should be reduced by at least 400–500 kcal (1 kcal = 4.184 kJ), (3) the patients' saturated fatty acid intake should be less than 30% of their total fatty acid intake and (4) the patients should be encouraged to engage in moderate‐intensity physical activity for at least 150 min/week.

T2DM prevention through medical intervention

Drug intervention trials in a pre‐diabetic population showed that the oral administration of hypoglycaemic agents, such as metformin, α‐glucosidase inhibitors, thiazolidinediones (TZDs), metformin combined with TZDs, the diet pill orlistat and traditional Chinese herbal medicine (Tianqi capsules), reduced the risk of diabetes 13, 17, 18, 19, 20, 21. However, because there is no sufficient evidence showing that drug interventions have long‐term efficacy and/or health economics benefits, the clinical guidelines developed by various countries have not widely recommended medical interventions as the primary prevention for diabetes. Given that economic development in China is still in the preliminary stage and significant regional imbalances exist and that diabetes prevention‐related health care is currently unsophisticated and imperfect, this guideline currently does not recommend the use of drug interventions to prevent diabetes.

Strategies for the secondary prevention of T2DM

Blood glucose control

The clinical trials on intensive glucose control, such as the Diabetes Control and Complications Trial (DCCT) 22, the United Kingdom Prospective Diabetes Study (UKPDS) 23 and the Kumamoto Study in Japan 24, found that among patients in the early stage of diabetes, intensive glucose control can significantly reduce the risk of diabetic microvascular diseases. The UKPDS study also showed that in obese or overweight populations, the use of metformin was correlated with a significant decrease in the risk of myocardial infarction and death 25. The long‐term follow‐up studies of the DCCT and UKPDS patient populations indicated that early intensive glycaemic control was correlated with a reduction in diabetic microvascular diseases and a significant decrease in the risks of myocardial infarction and death 26, 27. These results provide evidence that intensive blood glucose control during the early stages of T2DM can reduce the risks of diabetic macrovascular and microvascular diseases.

This guideline recommends that for newly diagnosed diabetes patients and early T2DM patients, strict glycaemic control strategies should be adopted to reduce the risk of diabetic complications.

Blood pressure control, lipid control and aspirin use

The UKPDS study showed that in patients newly diagnosed with diabetes, intensive blood pressure control not only significantly reduced the risk of diabetic vascular diseases but also the risk of microvascular diseases 28. An analysis of a subgroup in a trial of hypertensive optimization therapy and other clinical trials of anti‐hypertensive therapy also showed that intensive blood pressure control reduced the risk of cardiovascular diseases in diabetic patients without significant vascular complications 28, 29. The British Heart Protection Study–subgroup analysis of diabetic patients 30, the Collaborative Atorvastatin Diabetes Study 31 and other large‐scale clinical studies 32 indicated that the use of statins to lower low‐density lipoprotein cholesterol (LDL‐C) could reduce the risk of cardiovascular diseases in diabetic patients without causing significant vascular complications. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study showed that the combination of statins and lipid‐lowering drug did not achieve additional cardiovascular benefits, as compared with statins alone 32. The results of clinical trials using aspirin for the primary prevention of cardiovascular diseases in diabetic patients varied 33, 34; therefore, whether aspirin has a protective effect in the primary prevention of cardiovascular diseases in diabetes patients remains unclear. Nevertheless, a systematic review of multiple clinical trials demonstrated that among patients with T2DM and cardiovascular disease risk factors, aspirin showed a certain cardiovascular protective effect 35.

This guideline recommends that for T2DM patients without significant diabetic vascular complications but with risk factors for cardiovascular diseases, controlling blood glucose, lowering blood pressure and adjusting lipids (mainly to reduce LDL‐C) and aspirin therapy are all useful methods to prevent cardiovascular diseases and diabetic microvascular diseases.

Strategies for the tertiary prevention of T2DM

The clinical findings in intensive glucose control trials such as DCCT, UKPDS, Kumamoto, The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), and the Veterans Affairs Diabetes Trial (VADT) suggest that intensive glucose control reduced the progression of diabetic microvascular diseases (e.g. background diabetic retinopathy and microalbuminuria) 22, 24, 28, 36, 37.

Among patients who have already developed severe diabetic microvascular diseases, relevant clinical evidence is still necessary to verify whether intensive glucose control measures can reduce the risks of blindness, kidney failure and amputation.

The results of clinical trials such as ADVANCE, ACCORD and VADT all suggest that for patients with a longer duration of diabetes, who are older in age and who have multiple cardiovascular risk factors or cardiovascular diseases, the use of intensive glucose control measures does not reduce the risks of cardiovascular diseases and death. Conversely, the ACCORD study showed that in the aforementioned described population, intensive glucose control was correlated with an increased risk of all‐cause mortality 38.

This guideline recommends that for patients who are older and who have a longer diabetes duration and cardiovascular diseases, the pros and cons of adopting intensive glucose control must be cautiously evaluated. In addition, an individualized strategy should be used and, a patient‐centred diabetes management system should be developed to determine glycaemic control targets.

There is sufficient clinical evidence that in patients with T2DM who have had cardiovascular diseases, lowering blood pressure, lowering lipids, or the proper use of aspirin therapy alone or in combination can reduce the risk of cardiovascular disease recurrence and death 35, 39, 40, 41, 42, 43. In patients with diabetic nephropathy, the use of blood pressure‐lowering agents, particularly the use of angiotensin‐converting enzyme inhibitor or angiotensin II receptor antagonist drugs, significantly reduced the risk of diabetic nephropathy progression 43.

This guideline recommends that for older patients who have had a long diabetes duration and cardiovascular disease, in terms of individualized glycaemic control, measures such as lowering blood pressure, adjusting lipids (mainly to reduce LDL‐C) and taking aspirin should be used to reduce the risk of recurrent cardiovascular diseases and death and to reduce the risk of diabetic microangiopathy.

Diabetes education and management

The risks of microvascular and macrovascular diseases in diabetic patients are significantly higher than in non‐diabetic patients, and reducing these risks in diabetic patients depends not only on controlling high blood glucose but also on addressing other cardiovascular disease risk factors and improving lifestyle. In addition to drug therapy, diabetes control must also monitor blood glucose and other cardiovascular risk factors so as to determine whether the control reaches the target or whether the treatment must be adjusted. Moreover, as diabetes is a lifelong disease, the patient behaviour and self‐management ability are keys to successful diabetes control; further, diabetes control is not a treatment in the traditional sense but a management approach in nature.

Objectives of integrated T2DM control and treatment options for high blood glucose

Objectives for comprehensive T2DM control

The ideal comprehensive control of T2DM varies according to the age, comorbidities and complications of patients (Table 4). A treatment that does not achieve the control targets should not be viewed as a failure because any improvement in the control indicators confers benefits to the patient and reduces the risks associated with complications; for example, reductions in HbA1c are closely correlated with reductions in microvascular complications and neuropathy.

Table 4

Targets for the integrated control of type 2 diabetes mellitus in China

Indicator	Target value
Blood glucose (mmol/L)a
Fasting	4.4–7.0
Non‐fasting	<10.0
Glycated haemoglobin (%)	<7.0
Blood pressure (mmHg)	<140/80
Total cholesterol (mmol/L)	<4.5
High‐density lipoprotein cholesterol (mmol/L)
Male	>1.0
Female	>1.3
Triglycerides (mmol/L)	<1.7
Low‐density lipoprotein cholesterol (mmol/L)
Not complicated with coronary heart disease	<2.6
Complicated with coronary heart disease	<1.8
Body mass index (kg/m2)	<24.0
Urinary albumin/creatinine ratio [mg/mmol (mg/g)]
Male	<2.5 (22.0)
Female	<3.5 (31.0)
Urinary albumin excretion rate [µg/min (mg/dL)]	<20.0 (30.0)
Active aerobic activity (min/week)	≥150.0

Capillary blood glucose.

The primary principle for determining the targets for integrated T2DM control is individualization management, which should comprehensively consider age, disease duration, life expectancy, severity of complications or comorbidities and other relevant factors of patients.

Hypertension is a common complication of diabetes. Younger patients and those with a shorter disease duration may not require much treatment to reduce blood pressure to 130/80 mmHg or less. The target blood pressure value for elderly patients may be adjusted to 150/90 mmHg.

T2DM blood glucose control strategy and treatment options

T2DM is a progressive disease. The blood glucose tends to increase gradually as the disease duration increases; therefore, the intensity of hyperglycaemia control treatment should be increased accordingly. Lifestyle intervention is the basis for T2DM treatment and should be applied throughout the diabetes treatment process. When lifestyle change alone is unable to reach blood glucose target, drug treatment should be initiated. The preferred first‐line drug for T2DM is metformin. If no contraindications are present, metformin should remain part of the diabetes treatment regimen. Patients who could not take metformin may use α‐glucosidase inhibitors or insulin secretagogues. When metformin alone is unable to achieve blood glucose target, insulin secretagogues, α‐glucosidase inhibitors, dipeptidyl peptidase IV (DPP‐4) inhibitors or TZDs (a second‐line treatment) can be added. Patients who could not take metformin may undergo combination therapy with other oral medicines. When a combination therapy of two types of oral medicines still unable to achieve blood glucose target, insulin may be added (once‐daily basal insulin or once‐daily or twice‐daily premixed insulin), or a combination of three types of oral medicines may be initiated. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists can be used as a third‐line treatment. When basal insulin or premixed insulin combined with other oral medications is still unable to achieve blood glucose target, the regimen should be adjusted to include multiple daily injections of insulin (basal insulin plus prandial insulin or thrice‐daily premixed insulin analogues). When treating with premixed insulin and multiple insulin injections, insulin secretagogue use should be discontinued.

Based on the principles mentioned above, and the recommendations of International Diabetes Federation (IDF) 44, the American Diabetes Association (ADA) 45 and National Institute for Health and Clinical Excellence (NICE) 46, the treatment pathways for hyperglycaemia in T2DM are proposed and shown in Figure 1.

Figure 1

The treatment algorithm for high blood glucose in T2DM. The blue paths are the recommended primary drug treatment paths based on comprehensive considerations, including clinical evidence of the drug's health economics, efficacy and safety and China's national conditions. These paths are similar to the drug treatment pathways recommended by most international diabetes guidelines. The orange paths are alternative paths for the corresponding blue paths. HbA1c, glycated haemoglobin; DPP‐4, dipeptidyl peptidase IV; TZD, thiazolidinedione; GLP‐1, glucagon‐like peptide‐1

Medical nutrition therapy for T2DM

Principles of nutrition therapy

Patients with diabetes or prediabetes require individualized medical nutrition therapy. Such treatment should be provided under the guidance of a dietician or an integrated management team (including a diabetes educator) who is familiar with diabetes treatment. To achieve the metabolic control objective for patients and satisfy his or her dietary preference, reasonable quality objects should be established. In order to control the total energy intake and distribute various nutrients in a reasonable and balanced manner, the nutrition status should be evaluated before setting reasonable quality objectives. For overweight or obese patients, this guideline recommends moderate weight loss measures combined with physical exercise and behavioural changes to maintain weight loss outcomes.

Objectives of medical nutrition therapy

Maintaining a proper body weight: the weight loss goal for overweight/obese patients is 5–10% of body weight in 3–6 months. People who are underweight should recover and maintain an ideal body weight over the long term via a sound nutrition plan.

Providing balanced nutritious meals.

Achieving and maintaining an ideal blood glucose level and reducing the HbA1c level.

Reducing the risk factors for cardiovascular disease, dyslipidemia and hypertension.

Reducing insulin resistance and pancreatic β‐cell load.

Exercise therapy for T2DM

Exercise plays an important role in the comprehensive management of T2DM. Regular exercise increases insulin sensitivity, helps control blood glucose, reduces cardiovascular risk factors, reduces weight and improves overall well‐being 47, 48. Moreover, exercise has a remarkable primary preventive effect on populations at high risk of diabetes 49. Epidemiological studies have shown that the regular exercise of more than 8 weeks reduced the HbA1c level by 0.66% and that the mortality of diabetes patients who adhered to regular exercise for 12–14 years significantly decreases 47.

Smoking cessation

Every diabetic smoker should be advised to stop smoking or using tobacco products. Patients' smoking status and the extent of nicotine dependence should be assessed. Brief consultations and hotlines for quitting should be provided, and if necessary, medications should be prescribed to help patients quit smoking.

Drug treatments for hyperglycaemia

Oral antihyperglycaemic medications

Medical nutrition therapy and exercise treatment are basic for controlling high blood glucose in T2DM. When diet and exercise cannot effectively control the blood glucose level, medication therapy, including oral medications, should be provided in a timely manner.

T2DM is a progressive disease. During the natural course of T2DM, pancreatic β‐cell function gradually decreases, meanwhile insulin resistance undergoes less change. Thus, as T2DM progresses, the reliance on exogenous glycaemic control measures gradually increases. Clinical treatment often requires the use of oral medication and a combination of oral medication and injectable anti‐diabetic medications (e.g. insulin and GLP‐1 receptor agonists).

Metformin

Metformin hydrochloride is the primary biguanide medication currently used in medical practice. The major pharmacological effect of biguanides is lowering blood glucose by reducing the hepatic glucose output and improving peripheral insulin resistance. The diabetes treatment guidelines of many countries and international organizations recommend metformin as the basic medication among the first‐line medications and combinations for control of hyperglycaemia in T2DM 44, 45, 50. Systematic reviews of clinical trials have shown that metformin can reduce HbA1c by 1.0–1.5% and can also reduce body weight 51. The efficacy of metformin has been shown to be separate from the body weight reduction. The UKPDS study results showed that metformin also decreased the likelihood of cardiovascular events and death in obese patients with T2DM 25. In China, randomized controlled clinical trials have been conducted to investigate the effect of metformin and sulfonylureas on recurrent cardiovascular events in patients with T2DM combined with coronary heart disease, and the results showed that metformin treatment was correlated with a significant reduction of major cardiovascular events. Metformin alone did not cause hypoglycaemia, but the combination of metformin and insulin or insulin secretagogues increased the risk of hypoglycaemia. The main side effect of metformin was gastrointestinal reactions. Starting with a small dose and gradually increasing the dosage was an effective way to reduce adverse reactions. The efficacy of metformin was unaffected by body weight 52. The relationship between biguanides and lactic acidosis risk is uncertain 53.

Biguanides are contraindicated in patients with renal insufficiency [serum creatinine >132.6 µmol/L (1.5 mg/dL) for men, >123.8 µmol/L (1.4 mg/dL) for women or estimated glomerular filtration rate (eGFR) <45 mL/min], liver dysfunction, serious infections, hypoxia or those undergoing major surgery. Metformin should be temporarily discontinued for patients undergoing angiography with iodinated contrast agents.

Sulfonylureas

Sulfonylureas are insulin secretagogues, and their main pharmacological effect is increasing the insulin level by stimulating insulin secretion from pancreatic β‐cells, therefore lowers the blood glucose level 54. Clinical trials have shown that sulfonylureas can reduce HbA1c by 1.0–1.5% 55. At present, sulfonylureas are the primary medications recommended in the diabetes treatment guidelines of many countries and international organizations. Prospective and randomized clinical studies have shown that the use of sulfonylureas was correlated with reduced risks of diabetic microvascular and macrovascular diseases 28. Currently, the main commercially available sulfonylureas in China are glyburide, glimepiride, gliclazide, glipizide and gliquidone. Sulfonylureas, if used improperly, can lead to hypoglycaemia, particularly in elderly patients and in those with liver and kidney dysfunctions; sulfonylureas may also cause weight gain. Patients with mild renal insufficiency should use gliquidone. Patients who exhibit poor compliance can take sulfonylurea drugs once a day. Xiao Ke Wan is a fixed dose combination drug containing glibenclamide and various traditional Chinese medicines (TCM) that have a antihyperglycaemic effect similar to that of glyburide. Compared with glyburide, Xiao Ke Wan carries a lower risk of hypoglycaemia and yields a more pronounced improvement of diabetes‐related TCM symptoms 56.

TZDs

Thiazolidinediones decrease blood glucose primarily by increasing the target cells' sensitivity to the action of insulin. Currently, the main commercially available TZDs in China are rosiglitazone and pioglitazone. Clinical trials have shown that TZDs can decrease HbA1c by 1.0–1.5% 55.

Thiazolidinediones do not cause hypoglycaemia when used alone, but they may increase the risk of hypoglycaemia when used in combination with insulin or insulin secretagogues. Weight gain and oedema are common side effects of TZDs, and these side effects are more remarkable when TZDs are used in combination with insulin. TZD use has been correlated with increase risk of fractures and heart failure 57. Patients with heart failure (New York Heart Association heart function classification class II and above), active liver disease, transaminase elevations exceeding 2.5 times the upper limit of normal, and severe osteoporosis and fractures should not take TZDs.

Glinides

Glinides are non‐sulfonylurea insulin secretagogues. The currently available glinides in China are repaglinide, nateglinide and mitiglinide. This class of medications reduces postprandial blood glucose by stimulating insulin secretion in the early phase, and they can lower HbA1c by 0.5–1.5% 55. These medications must be taken immediately before a meal and can be used separately or in combination with other anti‐diabetic medications (except sulfonylurea). The systematic reviews of clinical studies conducted on T2DM patients in China showed that in terms of reducing HbA1c, repaglinide was superior to placebo and sulfonylureas and was equivalent to α‐glucosidase inhibitors, nateglinide, metformin and TZDs. A systematic review of clinical studies of Asian populations with T2DM, including Chinese people, showed that in terms of reducing HbA1c, nateglinide worked better than α‐glucosidase inhibitors and was similar to sulfonylureas, repaglinide and mitiglinide 58. For newly diagnosed T2DM patients, combination therapy using repaglinide with metformin reduced HbA1c more significantly than repaglinide alone but with a significantly increased risk of hypoglycaemia 59.

Common side effects of glinides are hypoglycaemia and weight gain, but the risk and degree of hypoglycaemia are lower with glinides than with sulfonylureas. Glinides can be used in patients with renal insufficiency.

α‐Glucosidase inhibitors

α‐Glucosidase inhibitors reduce postprandial blood glucose by inhibiting carbohydrate absorption in the upper small intestine. They are suitable for patients who consume carbohydrates as their main food ingredient and experience postprandial hyperglycaemia. In China, commercially listed α‐glucosidase inhibitors include acarbose, voglibose and miglitol. Systematic reviews of clinical studies conducted on the T2DM population, including Chinese patients, showed that α‐glucosidase inhibitors could reduce HbA1c by 0.50% and cause weight loss 60. Clinical studies of Chinese people with T2DM showed that the hypoglycaemic effect of a daily dose of 300 mg of acarbose was equivalent to that of a daily dose of 1500 mg of metformin 61. α‐Glucosidase inhibitors can be combined with biguanides, sulfonylureas, TZDs or insulin.

Common adverse reactions to α‐glucosidase inhibitors are gastrointestinal reactions, such as abdominal distension and flatulence. Starting with a small dose and gradually increasing the dosage are effective way to reduce adverse effects. The use of this class alone usually does not lead to hypoglycaemia and may reduce the risk of preprandial reactive hypoglycaemia; no adjustments in medication dosage and frequency are necessary for elderly patients, no increase in the incidence of hypoglycaemia occurs and this medication is well tolerated. When patients using combination therapy with α‐glucosidase inhibitors manifest hypoglycaemia, glucose or honey can be used as treatments; dietary sucrose and starchy foods have a poor ability to correct hypoglycaemia.

DPP‐4 inhibitors

Dipeptidyl peptidase IV (DPP‐4) inhibitors enhance endogenous levels of GLP‐1 by reducing the deactivation of GLP‐1 in vivo through inhibition of DPP‐4. GLP‐1 enhances insulin secretion in a glucose concentration‐dependent manner and inhibits glucagon secretion. Currently, the commercially available DPP‐4 inhibitors in China include sitagliptin, saxagliptin, vildagliptin, linagliptin and alogliptin. Clinical trials in T2DM patients in China showed that sitagliptin, saxagliptin and vildagliptin can reduce HbA1c by 0.70–0.90%, 0.40–0.50% and 0.50%, respectively 62, 63, 64; a comparison study showed that the HbA1c‐lowering effect of vildagliptin was similar to that of acarbose 64 and that linagliptin and alogliptin can reduce HbA1c by 0.68% and 0.57–0.68%, respectively. Notably, the HbA1c‐lowering extent of DPP‐4 inhibitors is related to the patient's baseline HbA1c level, that is, the higher the baseline HbA1c level, the much it will be reduced by DPP‐4 inhibitors. The use of DPP‐4 inhibitors alone does not increase the risk of hypoglycaemia. DPP‐4 inhibitors have a neutral effect on body weight or may increase it. Saxagliptin, alogliptin and sitagliptin do not increase the risk of cardiovascular disease, pancreatitis and pancreatic cancer. When sitagliptin, saxagliptin, alogliptin or vildagliptin is prescribed for patients with renal dysfunction, the dosage must be reduced according to the instructions of medication. When using linagliptin in patients with liver or renal insufficiency, dosage adjustments are unnecessary.

GLP‐1 receptor agonists

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduce blood glucose by activating GLP‐1 receptors. They enhance insulin secretion and inhibit glucagon secretion in a glucose concentration‐dependent manner and can delay gastric emptying, thus reducing food intake via central appetite suppression. Currently, in the Chinese domestic market, the available GLP‐1 receptor agonists are exenatide and liraglutide, both require subcutaneous injection. GLP‐1 receptor agonists effectively lower blood glucose; and also significantly reduce body weight and improve triglycerides and blood pressure. GLP‐1 receptor agonists alone do not significantly increase the risk of hypoglycaemia. Clinical trials of patients with T2DM, including Chinese patients, showed that the HbA1c‐lowering effect of liraglutide was similar to that of glimepiride, leading to a body weight loss of 1.8–2.4 kg and a decrease in systolic blood pressure of approximately 3 mmHg 65; additionally, exenatide reduced HbA1c by 0.8% and body weight by 1.6–3.6 kg 66. GLP‐1 receptor agonists may be used alone or in combination with other oral antihyperglycaemic agents. A number of clinical studies have shown that when used after the failure of an oral antihyperglycaemic agent (metformin or sulfonylurea), GLP‐1 receptor agonists showed better efficacy than the active control drug 67. Common side effects of GLP‐1 receptor agonists are gastrointestinal symptoms (e.g. nausea and vomiting), which occur mainly in the initial stage of treatment and gradually diminish with treatment time increased.

Insulin

Initial treatment with insulin

Basal insulin or premixed insulin can be used to initiate insulin therapy.

Short‐term intensive insulin therapy programme for newly diagnosed T2DM patients.

For newly diagnosed T2DM patients with HbA1c >9.0% or FPG >11.1 mmol/L and with hyperglycaemic symptoms, short‐term intensive insulin therapy may be implemented 68, 69, 70, 71. The appropriate treatment duration is 2 weeks–3 months, with a therapeutic target of 3.9–7.2 mmol/L for fasting blood glucose and ≤10.0 mmol/L for non‐fasting blood glucose, without considering the HbA1c target as treatment objective. Intensive insulin therapy should be combined with medical nutrition, exercise therapy and diabetes education. Intensive insulin treatment regimen include a basal‐prandial insulin regimen [multiple subcutaneous insulin injections or continuous subcutaneous insulin infusion (CSII)] or premixed insulin injections two or three times a day.

For patients who fail to achieve treatment goals after short‐term intensive insulin therapy, the decision to continue insulin therapy or to switch to another medication should be based on the patient‐specific conditions as determined by a diabetes specialist. For patients have reached the therapy target, regular (e.g. every 3 months) follow‐up monitoring should be planned; if blood glucose increases again (i.e. FPG >7.0 mmol/L or 2‐h PG >10.0 mmol/L), the medication should be re‐initiated.

Intensive insulin therapy programme

CSII

CSII is a form of intensive insulin therapy delivered via an insulin pump. The main appropriate populations are T1DM patients, women with diabetes who are pregnant or expect to become pregnant, pregnant women who require insulin therapy and patients with T2DM who require intensive insulin therapy.

The insulin treatment paths are shown in Figure 2.

Figure 2

Insulin treatment paths for T2DM. HbA1c, glycated haemoglobin; FPG, fasting plasma glucose; CSII, continuous subcutaneous insulin infusion

Hypoglycaemia

During treatment, patients may experience hypoglycaemia, which may cause discomfort and can be life‐threatening. Hypoglycaemia poses a major obstacle to reaching the blood glucose target and warrants special attention.

Bariatric surgery to treat T2DM

Indications for bariatric surgery

Patients with T2DM who are 18 to 60 years old are generally in good condition, have a low surgical risk and are difficult to control the disease or concomitant diseases (HbA1c >7.0%) after lifestyle interventions and various drug treatments and who meet the following conditions may consider bariatric surgery.

Indications: gastrointestinal bariatric surgery is feasible if the patient has a BMI ≥32 kg/m2 with or without diabetic complications.

Precautions: bariatric surgery could be considered with caution for T2DM patients with a BMI of 28–32 kg/m2, particularly in the presence of other cardiovascular risk factors.

Not recommended: patients with a BMI 25–28 kg/m2, with diabetic complications and central obesity (waist circumference >90 cm in men and >85 cm in women) and at least two additional metabolic syndrome components: high triglycerides, low HDL‐C and high blood pressure. Surgery should be conducted in strict accordance with study protocol with the patient's informed consent. The operation should be regarded as pure for clinical research and must be approved by the Medical Ethics Committee in advance; currently, evidence is insufficient, and surgery is not recommended as a clinical routine treatment.

Contraindications for bariatric surgery

Patients abuse drugs, addict to alcohol or have a mental illness that is difficult to control, and who are lack the ability to understand the risks, benefits and expected consequences of bariatric surgery.

Patients with confirmed, diagnosed T1DM.

T2DM patients who have a clear failure of pancreatic β‐cell function.

Contraindications for surgery.

BMI <25 kg/m2.

GDM and other specific types of diabetes.

Chronic complications of diabetes

Diabetic nephropathy

Approximately 20–40% of diabetic patients suffer from diabetic nephropathy, which is the main cause of renal failure in diabetes patients 72, 73.

Diagnosis

Diagnosis of diabetic nephropathy: T1DM‐induced renal damage is divided into five stages, which are also used for T2DM‐induced renal damage: stage I, elevated glomerular filtration rate and increased renal size; stage II, intermittent microalbuminuria; stage III, early diabetic nephropathy with persistent microalbuminuria; stage IV, clinical diabetic nephropathy with overt albuminuria; and stage V, renal failure. Diabetic nephropathy is an important type of chronic kidney disease; for diabetic nephropathy patients, the eGFR should be calculated using the Modification of Diet in Renal Disease Study equation or the Cockcroft–Gault formula (Table 5) 74, 75, 76, 77.

Table 5

Stages of renal function in CKD

CKD stage		Feature description	eGFR [mL/(min · 1.73 m2)]
1		Increased GFR or normal GFR with kidney damagea	≥90
2		Slightly decreased GFR with kidney damagea	60–89
3	3a	Mild to moderate GFR decrease	45–59
	3b	Moderate to severe GFR decrease	30–44
4		Severe GFR decrease	15–29
5		Kidney failure	<15 or dialysis

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate.

Kidney injury is defined as an abnormality in pathological, urine, blood or imaging examinations.

Treatment

Lifestyle changes: reasonable weight control, diabetic diet, smoking cessation, proper exercise and so on

Low‐protein diet.

Control blood glucose.

Control blood pressure.

Correct dyslipidemia.

Control proteinuria: starting from the early stages of diabetic nephropathy (microalbuminuria) with or without hypertension, renin‐angiotensin system inhibitors (angiotensin‐converting enzyme inhibitor or angiotensin II receptor antagonist drugs) are the preferred drugs for reducing urinary albumin 78, 79, 80. Because these drugs may also lead to a short‐term decline in the GFR in the first 1–2 weeks, serum creatinine and potassium concentrations must be monitored. Renin‐angiotensin system inhibitors are not recommended for patients with serum creatinine levels >265.2 µmol/L (3 mg/dL).

Dialysis therapy and transplantation: when the eGFR is less than 60 mL/(min · 1.73 m2), the potential complications of chronic kidney disease should be assessed and treated. Diabetic patients with kidney failure who require dialysis or transplant treatments should undergo these procedures as soon as possible. Generally, when the GFR drops to 15–20 mL/min or the serum creatinine level is higher than 442 µmol/L (5 mg/dL), dialysis, either peritoneal dialysis or haemodialysis, should be prepared. When conditions permit, a kidney or pancreas‐kidney transplant could be performed.

Diabetic retinopathy

Diabetic retinopathy is the most common cause of new onset blindness among adults aged 20–74 years.

Screening

Patients with non‐proliferative diabetic retinopathy and macular oedema may have no obvious clinical symptoms; therefore, in terms of preventive treatment, regular fundus examinations are particularly important.

Follow‐up frequency: diabetic patients without retinopathy are recommended to undergo follow‐up check‐up once every 1–2 years; patients with mild retinopathy should be checked once a year, and patients with severe retinopathy should be checked once every 3–6 months. The frequency of check‐up should be increased for pregnant women.

Diabetic retinopathy is graded according to the observable indicators after dilation under ophthalmoscope. The international clinical grading standard for diabetic retinopathy is shown in Table 6.

Table 6

International clinical grading standard for diabetic retinopathy (2002)

Disease severity	Observation after dilation under ophthalmoscope
No obvious diabetic retinopathy	No abnormality
NPDR
Mild	Diabetic microaneurysm only
Moderate	Diabetic microaneurysm with mild or moderate NPDR
Severe	Any of the following, but without PDR
	1. More than 20 intraretinal haemorrhages in any one quadrant
	2. Retinal venous beading in two or more quadrants
	3. Intraretinal microvascular abnormalities in one or more quadrants
Proliferative diabetic retinopathy	One or more of the following: new vessels at the optic disc, vitreous haemorrhage or preretinal haemorrhage

NPDR, non‐proliferative diabetic retinopathy.

Good control of blood glucose, blood pressure and lipids may prevent or delay the progression of diabetic retinopathy 81, 82.

Patients with sudden blindness or retinal detachment require an immediate referral to an ophthalmologist; diabetic patients with any degree of macular oedema, severe non‐proliferative diabetic retinopathy or any proliferative diabetic retinopathy should be referred to an ophthalmologist with extensive experience in diagnosing and treating diabetic retinopathy.

Laser photocoagulation therapy may reduce high‐risk proliferative diabetic retinopathy, clinically significant macular oedema and the risk of blindness in some patients with severe non‐proliferative diabetic retinopathy 83.

Anti‐vascular endothelial growth factor therapy may be used to treat patients with diabetic macular oedema 84.

Retinopathy is not a contraindication for aspirin therapy; aspirin therapy does not increase the risk of retinal haemorrhage.

Fenofibrate may slow the progression of diabetic retinopathy and decrease the need for laser treatment.

Diabetic neuropathy

Diabetic neuropathy is one of the most common chronic complications of diabetes. Neuropathy may affect the central nervous system or, more commonly, the peripheral nerves 85.

Diabetic peripheral neuropathy refers to peripheral nerve dysfunction‐related symptoms or signs in diabetic patients that cannot be attributed to other causes. Distal symmetric polyneuropathy is a typical diabetic neuropathy. The diagnosis of other asymptomatic diabetic neuropathies relies on the screening of clinical signs or electrophysiological examination 86.

Prevention

(1) General treatment: good blood glucose control, correction of dyslipidemia and hypertension control. (2) Regular disease screening and evaluation: all patients should undergo screening for diabetic peripheral neuropathy at least once a year after the diagnosis of diabetes. For patients with a long course of diabetes or microvascular complications, such as retinopathy and nephropathy, check‐up should occur every 3–6 months. (3) Increased foot care: patients suffering from peripheral neuropathy should receive education about foot care to reduce the incidence of foot ulcers 87.

Etiological therapy

(1) Glycaemic control. (2) Nerve repair: commonly used medications, such as methylcobalamin and growth factors, may be useful. (3) Anti‐oxidative stress: commonly used medications, such as lipoic acid, may be useful. (4) Improved microcirculation: commonly used medications include prostaglandin E1, beraprost natriuretic peptide, cilostazol, pentoxifylline, pancreatic kallikrein, calcium antagonists and blood circulation‐promoting TCM 88.

Symptomatic treatment

Medications for the treatment of painful diabetic neuropathy include anticonvulsants (pregabalin, gabapentin, valproate and carbamazepine), antidepressants (duloxetine, amitriptyline, imipramine and citalopram), opioids (tramadol and oxycodone) and capsaicin 87, 88.

Lower extremity vascular disease

Lower extremity vascular disease mainly refers to peripheral artery disease; although it is not a complication specific to diabetes, the risk of peripheral artery disease in patients with diabetes significantly increases compared with patients without diabetes. In addition, patients with diabetes also have an earlier age of onset and increased severity of lower extremity vascular disease, as well as more extensive pathology and worse prognoses 82.

Lower extremity arterial disease

Lower extremity arterial disease (LEAD) is a component of peripheral artery disease that manifests as lower extremity arterial stenosis or occlusion.

Screening for diabetic LEAD

For diabetes patients over age of 50 years, LEAD screening should be conducted routinely 89, 90. For diabetes patients with LEAD‐associated risk factors (e.g. cardiovascular disease, dyslipidemia, hypertension, smoking or a diabetes duration of more than 5 years) should be screened at least once a year.

For diabetes patients with foot ulcers and gangrene, regardless of their age, a comprehensive examination and evaluation of arterial disease should be conducted.

Diagnosis of diabetic LEAD

(1) If the patient has a resting ABI ≤0.90, regardless of the presence of lower limb discomfort, a LEAD diagnosis should be considered. (2) For a patient who experiences discomfort upon moving and has a resting ABI ≥0.90: if ABI decreases by 15–20% after a treadmill test, a LEAD diagnosis should be considered; (3) if the patient has a resting ABI <0.40, or ankle arterial pressure <50 mmHg or toe arterial pressure <30 mmHg, a critical limb ischaemia diagnosis should be considered.

Treatment of diabetic LEAD

The therapeutic approach to LEAD includes the prevention of systemic atherosclerotic disease progression, the prevention of cardiovascular events, the prevention of ischaemic‐induced ulcers and gangrene, the prevention of amputation or the reduction of the amputation level and the improvement of the functional status of patients with intermittent claudication. Therefore, the standard treatment for diabetic LEAD consists of three parts: primary prevention (to prevent or delay the occurrence of LEAD), secondary prevention (to relieve symptoms and delay LEAD progression) and tertiary prevention (to promote revascularization and reduce amputation and cardiovascular events).

Prevention and treatment of cardiovascular and cerebrovascular diseases in patients with T2DM

Diabetes is an independent risk factor for cardiovascular and cerebrovascular diseases. Patients with diabetes have 2–4 times higher risk of cardiovascular and cerebrovascular diseases 91, 92, 93 compared with patients without diabetes. FPG and postprandial hyperglycaemia are correlated with an increased risk of cardiovascular and cerebrovascular diseases, even when they do not reach the diagnostic criteria for diabetes. Diabetic patients often present important risk factors for cardiovascular and cerebrovascular diseases, such as dyslipidemia and hypertension 94, 95.

Clinical evidence suggests that strict glycaemic control in patients with T2DM has a limited effect on reducing the risks of cardiovascular and cerebrovascular diseases and death from those causes, particularly among patients with a longer disease duration, who are older, and who have a history of cardiovascular diseases or multiple cardiovascular risk factors 38. However, the comprehensive management of multiple risk factors can significantly decrease the risk of cardiovascular and cerebrovascular diseases and death from those causes in patients with diabetes. Therefore, the prevention of diabetic vascular diseases requires the comprehensive assessment and control of cardiovascular disease risk factors (e.g. high blood glucose, hypertension and dyslipidemia) and appropriate antiplatelet therapy.

At present, the incidence of cardiovascular risk factors is high among T2DM patients in China, and they are insufficiently controlled. Among outpatients with T2DM, only 5.6% achieved all triple therapeutic goals for HbA1c, blood pressure, and total cholesterol 96. The use of aspirin has also been low. Clinically, more active screening and treatment of cardiovascular risk factors and an increased rate of aspirin therapy are recommended.

The clinical decision‐making paths for screening and the lipid‐lowering, antihypertensive and antiplatelet treatments for patients with T2DM are shown in Figure 3.

Figure 3

The clinical decision‐making paths for screening and the standard lipid‐lowering, antihypertensive and antiplatelet treatments for patients with T2DM. ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist; LDL‐C, low‐density lipoprotein cholesterol

Metabolic syndrome

Diagnostic criteria for metabolic syndrome

According to an epidemiological analysis of metabolic syndrome in the current Chinese population, this guideline has revised the quantitative indicators of the metabolic syndrome components based on the CDS's 2004 recommendations 97. The diagnostic criteria are as follows: (1) abdominal obesity: waist circumference: men ≥90 cm and women ≥85 cm, (2) high blood glucose: fasting blood glucose ≥6.l mmol/L or glucose at 2 h after glucose load ≥7.8 mmol/L and/or diabetes diagnosis and treatment, (3) high blood pressure: blood pressure ≥130/85 mmHg and/or diagnosed and on antihypertension therapy, (4) fasting TG ≥1.70 mmol/L and (5) fasting HDL‐C < l.04 mmol/L. Patients with three or more of the aforementioned characteristics are diagnosed with metabolic syndrome.